Search results
25 cze 2022 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine c...
13 kwi 2023 · Our findings suggest that, in adults aged 65 years or older, the vaccine effectiveness of the bivalent mRNA vaccine booester dose is 72% (95% CI 60–81) for COVID-19 related hospitalisation and 68% (42–82) for COVID-19-related death. Implications of all the available evidence.
8 kwi 2022 · The COV-BOOST randomised controlled trial found that booster schedules increased both humoral and cellular responses to SARS-CoV-2, and that the side-effects were similar to those seen with primary vaccination.
23 mar 2022 · Active immunization with the BNT162b2 vaccine (Pfizer–BioNTech) has been a critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the...
16 mar 2022 · In this open-label, nonrandomized clinical study, we assessed the immunogenicity and safety of a fourth dose of either BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) administered 4 months ...
25 sty 2023 · Bivalent boosters provided substantial additional protection against severe omicron infection in persons who had previously been vaccinated or boosted, although the effectiveness waned over...
4 lis 2022 · Bivalent booster elicited approximately 4-fold higher neutralizing antibody titers against Omicron BA.4/BA.5 sublineages compared to the original COVID-19 vaccine in individuals older than 55 years of age.
